Create Account | Sign In: Author or Forum

Search Symptoms

Category: Family Medicine | Gynecology | Nursing | Pathology | Journal

Back to Journal Articles

Success More Than 50 Percent for Second Child With Fertility Treatment

Last Updated: May 29, 2020.

Women have a good chance of having a second child with the help of assisted reproductive technology, according to a study published online May 8 in Human Reproduction.

FRIDAY, May 29, 2020 (HealthDay News) -- Women have a good chance of having a second child with the help of assisted reproductive technology (ART), according to a study published online May 8 in Human Reproduction.

Repon C. Paul, from the University of New South Wales in Sydney, and colleagues evaluated success rates for women returning to ART treatment for a second ART-conceived child. Analysis included 35,290 women who began autologous ART treatment and achieved their first treatment-dependent live birth from treatment performed from January 2009 through December 2013, with follow-up through 2015.

The researchers found that among the women who had their first ART-conceived live birth, 43 percent returned to treatment. Compared to women who underwent a new ovarian stimulation cycle, live birth rates (LBRs) were consistently better in women who recommenced treatment with a previously frozen embryo. The cumulative LBR after six cycles was between 60.9 percent (conservative) and 88.1 percent (optimal) for women who recommenced treatment with a frozen embryo versus between 50.5 and 69.8 percent for those who underwent a new ovarian stimulation cycle. For women ≥35 years, who waited at least three years before returning to treatment, or who required either a higher number of ovarian stimulation cycles or double embryo transfer to achieve their first child, the adjusted odds of a second ART-conceived live birth decreased.

"These age-specific success rates can facilitate individualized counseling for the large number of patients hoping to have a second child using ART treatment," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text


Previous: ASCO: Relugolix Superior to Leuprolide in Advanced Prostate Cancer Next: Multiple Sclerosis Tied to Higher Risk for CVD, Cerebrovascular Disease

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: